AMAREG merges with Haupt Pharma and Wülfing Pharma
AMAREG specialises in the contract manufacturing of cytostatics, chemical compounds which inhibit cell growth and are used in the treatment of cancer, and also partly in the treatment of autoimmune disease. They interfere with the metabolism of tumour cells or destroy their cell structure. The location in Regensburg has a year long tradition in the manufacturing and development of medicines. AMAREG emerged from the international pharmaceutical concern Bristol-Myers-Squibb, which ran a production plant until the mid 90s in Regensburg. Currently 175 employees work at AMAREG, producing a turnover of 22 Million €.
Likewise Haupt Pharma is a concern rich in tradition, founded in Berlin in 1937 and represented with production plants in Germany, France, Malta and Japan with 900 employees. Wülfing Pharma located in Gronau in Hildesheim (Lower Saxony) has 300 employees and also has years of experience in the manufacture of medicines. Through the merger AMAREG has future access to additional technology and has thereby made an important step in maintaining growth in the European pharmaceutical industry, which is strongly influenced by consolidation. Closure of departments will not occur in the merger process. All three firms are portfolio companies of Invita AG, a joint venture company with its headquarters in Plettenberg in North Rhine-Westphalia, which invests globally in medium-sized pharmaceutical companies.
For more information see: